You are here: Industry Insights > Lilly

News List

Lilly’s CEO looks to M&A, but not for CAR-T or gene therapies pharmaphorum
January 15, 2019
Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop......
Novartis’ Aimovig fails to win NICE backing amid tight migraine fight with Lilly, Teva fiercepharma
January 13, 2019
Separately, the Institute for Clinical and Economic Review previously concluded that Aimovig’s use is cost-effective but only after patients try “existing preventive treatments, which are far less expensive.”
Don't fret about Lilly's 3rd-to-market start in CGRP, executive says. fiercepharma
January 10, 2019
Eli Lilly's Emgality didn't take the first-to-market crown in the budding CGRP field of migraine prevention drugs. It didn't even come in second.
Lilly Announces Agreement to Acquire Loxo Oncology americanpharmaceuticalreview
January 08, 2019
Eli Lilly and Company and Loxo Oncology announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion ......
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug fiercebiotech
December 27, 2018
Eli Lilly has paid CHF 80 million ($81 million) upfront for the worldwide rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease.....
Lilly, Aduro Biotech Announce Research Collaboration, License Agreement americanpharmaceuticalreview
December 20, 2018
Eli Lilly and Company and Aduro Biotech announced a research collaboration and exclusive license agreement for Aduro’s cGAS-STING Pathway Inhibitor program for .....
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
Dicerna agrees another gene-silencing deal, this time with Lilly pharmaphorum
December 18, 2018
Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist.
Lilly teams up with AC Immune for Alzheimer’s drug pharmaceutical-technology
December 14, 2018
Eli Lilly has signed a licence and collaboration agreement with Swiss biotech AC Immune for the research and development of tau aggregation inhibitor small molecules.....
Lilly and AC Immune Announce License and Collaboration Agreement pharmafocusasia
December 13, 2018
This transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page